Recon: MAHA report blames diet, prescription drugs as causes of chronic illness; FDA adcomm votes against Pfizer's prostate cancer combo

• Trump administration proposes cutting Food and Drug Administration budget by 5.5% (Reuters)
• In a significant change, House GOP tax cut bill would start Medicaid work requirements next year (STAT)
• House Republicans pass ‘big, beautiful bill’ after weeks of division (Politico)
• RFK Jr. Report Blames Diet, Overmedication for Chronic Diseases (Bloomberg) (Axios) (NYTimes)
• Five burning questions on the FDA’s new Covid-19 vaccine framework (STAT)
• Prices for new US drugs doubled in 4 years as focus on rare disease grows (Reuters)
• FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo (Endpoints)
• Teva, Novartis get fresh warnings from FTC over Orange Book patent listings (Endpoints)
• The FDA’s New Covid Vaccine Policy Is Clear as Mud (Bloomberg)
• FDA announces efforts to facilitate drug importation from Canada (Endpoints)
• Moderna pulls application for COVID-flu combination shot (Reuters)

• Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out (Pink Sheet)
• Global vaccine and health bodies could team up more to tackle US-led funding crisis (Reuters)
• ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials (Pink Sheet)
• Zentiva inks €220M deal for former AstraZeneca GI drug in Europe (Fierce Pharma)
• India's Sun Pharma posts bigger adjusted profit on demand for rare disease drugs (Reuters)
• India's Mankind Pharma beats profit estimates on demand for drugs to treat chronic illnesses (Reuters)

• Novo Offers Wegovy at $199 for First Month as Copycats End (Bloomberg)
• Novo Nordisk's former chief makes comeback to steer choice of new CEO (Reuters)
• Tourmaline drug cuts inflammation tied to heart disease (STAT)
• Biotech investor activism is on the rise (STAT)
• How do we know mRNA vaccines are safe and effective? An explainer (STAT)
• The new era of individualized medicine requires a ‘genetic surgery’ system (STAT)
• Sanofi makes $470M move for Vigil's Alzheimer's drug, while another asset returns to Amgen (Endpoints)
• Samsung Biologics to separate manufacturing and biosimilar businesses (Endpoints)
• Samsung Biologics, C&T Shares Volatile After Spin-Off Plan (Bloomberg)
• FDA asks Covid vaccine makers to add more myocarditis data to labels (Endpoints)
• Pfizer’s All-Comers CRPC Dream For Talzenna Quashed For Lack Of Biomarker-Negative Rigor (Pink Sheet)
• US CDC accepts recommendations for chikungunya vaccines (Reuters)

• ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines (STAT)
• Self-guided mental health apps can improve outcomes and lower costs, report finds (STAT)
• Hinge Health is going public on Thursday at a $3B valuation (Endpoints)
• AI-Generated Drugs to Reach Market by 2030, Says Insilico CEO (Bloomberg)
• Cost cuts, production shifts: How medtech firms are managing tariffs (MedTech Dive)
• Why Medtronic plans to spin out its diabetes business (MedTech Dive)

• Three big ideas to actually ‘Make America Healthy Again’ (STAT)
• Kraft Heinz confirms $3B investment in US manufacturing (Food Dive)
• Food industry fights for SNAP as program faces massive cuts (Food Dive)
• Study: AI Can Predict Listeria Resistance to Cleaning Agents (Food Safety)

• Trump, building on Biden policy, to speed up audits of Medicare Advantage insurers (STAT)
• LGBTQ+ researchers sue HHS, NIH over grant cuts (STAT)
• Trump’s R&D Funding Cuts Create Job Drought for Scientists (Bloomberg)
• One Analyst Saw the Dark Clouds Coming for UnitedHealth (Bloomberg)